AZD2098 is primarily utilized in medical research and drug development for cancer treatments, particularly those associated with EGFR (Epidermal Growth Factor Receptor) gene mutations. EGFR is a signaling receptor involved in the growth and division of cancer cells.

This compound is designed to inhibit the activity of mutated EGFR, especially the T790M mutation, which is commonly found in patients with non-small cell lung cancer (NSCLC) who have developed resistance to first-generation anti-EGFR drugs.

AZD2098 belongs to the class of EGFR tyrosine kinase inhibitors (TKIs), which function by blocking signaling pathways that promote cancer cell growth and spread. It holds potential for treating patients resistant to prior EGFR TKI therapies.

Additionally, AZD2098 is under investigation for efficacy against other cancers linked to EGFR mutations or abnormal EGFR expression. However, research remains in the experimental phase, requiring further studies to validate its efficacy and safety in humans.